David J. Dorer, Ph.D. has over twenty five years of experience as a Biostatistician in both industry and hospital based research. His background includes work with clinical trials and observational studies.
Ariad Pharmaceuticals Experience
-
Phase I, II, and III clinical trials: Design and Analysis.
-
Regulatory Filings for Drug Approval worldwide.
-
Safety Regulatory Filings FDA, Europe, Japan & Health Canada.
-
Postmarketing Safety Filings.
-
Two approved oncology compounds: Brigatinib (Non-Small Cell Lung Cancer) & Ponatinib (Chronic Myeloid Leukemia).
-
Statistician member Safety Managment Teams.
-
Statistician member Clinical Pharmacology Research Group.
-
Coauthor: Publications, Posters & Conference Presentations.
Massachusetts General Hospital
-
Phase III Clinical Trials: Design and Analysis.
-
Long Term Follow up Studies.
-
Medical Fields: neurology, surgery, pediatrics, infectious disease, rehabilitation medicine, psychiatry, endocrinology and cardiology.
-
Member Clinical Trial Data Safety Monitoring Committees.
-
Example Methods: Survival Analysis, Logistic Regression, Group Sequential Trials, Mixed Models.
-
Biostatistician MGH Statistical Consulting Service.
-
Instructor: Seminars for Physicians on Statistical Methods.
-
Coauthor: Grant Applications and Publications.
-
Co-Investigator: NIH Grants.
Education
-
Massachusetts Institute of Technology: Undergraduate and Graduate.
-
Harvard University & NASA Ames Research Center: Postdoctoral Research Fellow.
v1.4